Patient engagement is key in minimizing the risk of opioid use disorder and overdose. This engagement may include discussions between the patient and provider about treatment goals, expectations and risks, signs of dependence, and documented contracts or agreements outlining the responsibilities of both participants in the treatment process, with realistic, specific, and measurable goals focusing on improvement in pain and function. Patients should also receive information about pain management options and potential treatment outcomes, including benefits and risks of non-opioid pharmacotherapy, non pharmacological therapies, and opioid therapy.
The conclusion of this 3-part series features expert faculty focusing on a collaborative patient-centered approach in order to guide optimal pain management, which includes applying an evidence-based approach to chronic pain management and improving prescribing practices through pharmacovigilance.
At the end of this CME/CE activity, participants should be able to:
The following learning objectives pertain only to those requesting CNE or CPE credit:
Supported by an educational grant from Johnson & Johnson.
Physicians, dentists, physician assistants, nurse practitioners, and pharmacists
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Gold has no disclosures to report.
Dr. Abubaker has no disclosures to report.
Mr. Alden has no disclosures to report.
Ms. Judd reports that she is on the speakers bureau for Alkermes; Neurocrine Biosciences, Inc.; Otsuka America Pharmaceutical, Inc.; and Sunovion Pharmaceuticals Inc. She is on the advisory board for ACADIA Pharmaceuticals Inc.; and Neurocrine Biosciences, Inc.
Dr. Mir reports that he is a consultant for OrthoGrid Systems, Inc.; Smith & Nephew; StabilizOrtho; Trice Medical; and Zimmer Biomet.
Dr. Schmidt has no disclosures to report.
Dr. Stanos reports that he receives research support from Grunenthal and is a consultant for SCILEX Pharmaceuticals, Inc.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
CME Outfitters, LLC and the faculty do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.